Antibiotic use and reduced effectiveness of second-line immunotherapy for lung cancer: all the time or just at the start of treatment?
Publication date
2020-12
Authors
van de Garde, Ewoudt M.W.
van Bedaf, L R
Hurkmans, D P
van den Heuvel, M M
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
taverne
Abstract
Keywords
Anti-Bacterial Agents/therapeutic use, Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung, Humans, Immunotherapy, Lung Neoplasms/drug therapy, Proton Pump Inhibitors, Time, Taverne, SDG 3 - Good Health and Well-being
Citation
van de Garde, E M W, van Bedaf, L R, Hurkmans, D P & van den Heuvel, M M 2020, 'Antibiotic use and reduced effectiveness of second-line immunotherapy for lung cancer : all the time or just at the start of treatment?', Annals of Oncology, vol. 31, no. 12, pp. 1779-1780. https://doi.org/10.1016/j.annonc.2020.09.007